Novo Nordisk to outsource 33% of diabetes R&D to India
The company is also looking to collaborate with domestic firms for development of new molecules and plans to introduce three new anti-diabetic products in India within three years. Novo Nordisk has about 60% market share in the Rs 375-crore domestic insulin market and it is growing at a rate of 20% per annum.
Novo Nordisk is also working on developing a database of diabetics in the country and has launched mobile clinics in Bangalore and New Delhi. The mobile vans, besides diagnosing the disorder in and around the two cities free of cost, would build a database to understand the disease better, senior vice-president of Novo Nordisk, Jesper Hoiland, said.
"India is a key territory for the company and we would shift around 30% of our R&D work to India. The company is also carrying out clinical trials for its modern insulin at several locations in India," Hoiland said. When asked if the company plans to set up a manufacturing unit in India, vice-president international operations Novo Nordisk Sanjeev Shishoo said, "We have tied up with Ahmedabad-based drug maker Torrent Pharmaceuticals Ltd. They would set
Be the first to comment.